Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. - Wikidata - wikimedia - TriplyDB

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

http://www.wikidata.org/entity/Q36877036

about

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy Beyond hypomethylating agents failure in patients with myelodysplastic syndromes Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure Established and emerging targeted therapies in the myelodysplastic syndromes.Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.Myelodysplastic syndromes: Contemporary review and how we treat.Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study Epigenetic therapies in MDS and AML Current therapy of myelodysplastic syndromes Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1 in tumors of epithelial, NK- and B-cell origins.Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IP A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.Incidence and Burden of the Myelodysplastic Syndromes.BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.Azacitidine in the management of patients with myelodysplastic syndromes.Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.Concise drug review: azacitidine and decitabine Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.

P2860

Q24597616-E51E20AE-612D-4B45-8E69-4E3241B61301 Q24605618-3C257188-CF5C-4779-BEB8-188D61D5DD2F Q26743743-8DF09E2A-9A64-4908-8830-E13B9A556C56 Q26749870-47C273DC-C756-4B66-9CEC-8B73CA4381BF Q26827079-ADA85E5D-DB8F-45DB-BC1B-3496C402296A Q28084813-56320B70-5A62-46C5-8691-3ECD75DA1F15 Q28534843-11120631-B942-4AAF-8477-3929FCF340ED Q30245476-A252DEC5-242B-41C9-B7B5-DFDD3EE3EFA1 Q33162921-3A84B5EF-10B9-4EC9-BBEC-0B2CE278EFA2 Q33406190-DC7643F5-9C63-4BCA-A290-F12697319A3F Q33414866-37DBC9F4-DAD6-4C49-A075-C83B730D382C Q33429195-9E7ACF23-4E42-4FC8-9164-845E3FC0E34A Q33603472-C9241471-9B4B-4BA9-A9FC-DEC828F85068 Q33856972-B3928B17-1E49-4FEB-9CE1-C4AB9D02583F Q33863567-CEE21E7A-80C3-432E-8828-DDA9BEDD4D90 Q34013796-76B6543E-673A-4095-B53D-77233798A48A Q34013826-97343372-144C-471A-B24F-144459597CAC Q34212911-A7929E19-8F16-4765-8A5E-0F0B0E77AB17 Q34217884-181F3146-BF69-4875-ACA7-79006108FBE9 Q34273735-96B1869C-8E91-46AC-98DD-84E22B40A9CA Q34986440-F74EE233-7B90-42AC-ADA1-D6F299296A80 Q34986462-F5D269B6-8794-4785-B79C-15ED4CE4E76F Q35143275-3FA8C8A7-D38F-4153-ABB9-C9F848E5699A Q35230906-F5D90801-64AD-4190-A830-92254429CC0F Q35317371-C79F9D75-87EE-4501-B89A-CBA903723B74 Q35726371-C8552D8D-38F8-4949-A837-0754DF609540 Q35832463-885DF5D2-7EE5-4A1F-AC58-C803B5BBBF7D Q35854094-595D12BC-72EE-450F-B760-8189B561C201 Q36006077-B4C65161-983E-4830-A0AE-013949B0DFCC Q36050710-18CF9099-C61D-4AFA-8833-E00D59C6BB9F Q36179524-580FE8C7-C549-48F0-8E0D-1ADB021D0CAE Q36339459-F054E334-02E1-4B71-96F2-2DDC748802E1 Q36431041-EA22ACF7-2E2A-4DDA-B614-59653654DABE Q36642726-7E50EBB7-363D-4007-95A1-2F993EAA558F Q36768610-F7CCE25B-2922-44C9-8619-9A4DE13FE990 Q36789428-EF5D4ADC-6762-4EEA-81F9-5EBF14BA04A7 Q36811828-C9A4B60D-F5CB-497C-AAD8-3444411D13AA Q36871721-88B07C60-17ED-4FD9-8681-A875B35865F9 Q37074311-668254AE-86CB-49B4-AD67-772F78A8AB16 Q37158530-4FCF1EBB-D07B-4128-8F3B-684EFC46D8C2

P2860

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

http://www.wikidata.org/entity/Q36877036

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

@en

type

label

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

@en

prefLabel

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

@en

P1433

Q36877036-51397724-A94E-4B4C-B63C-48992BBFEF6E

P1476

Q36877036-6E32AC8F-7F8B-4ADA-B89D-8F622426C1F3

P2093

Q36877036-0926FEA4-06A7-4DB4-8ED1-2F11986FACED

Q36877036-19F0570B-D314-4145-AD1D-FBFDDA871F47

Q36877036-26A307CA-F1A7-4002-9861-2A643923B54B

Q36877036-3FB4864C-A02F-4ACF-87AA-11675E284409

Q36877036-71043400-7054-4736-9DA4-6AAE80B8828C

Q36877036-99375800-862E-4F7E-A719-ACF2A8BD2411

Q36877036-B21E82EF-F88C-4A0C-ACE4-79E7A24AE712

Q36877036-B37B0345-5CFE-4101-B50F-8F2B1AEF9521

Q36877036-D1D39E1C-E403-4167-84AC-3E73C9E9F378

Q36877036-DA64BF21-6924-425D-938F-656C1A91C9E4

P2860

Q36877036-04E3C76E-BA95-464E-AAE7-F4F4254F0B7E

Q36877036-2B693C47-AC41-4E85-AD00-22FC8C8F8CBC

Q36877036-2E44E83B-7B95-41D3-8672-322E3A672CC5

Q36877036-3539616B-FB1F-4281-8190-E3E316E9E884

Q36877036-372A388D-D069-41ED-9B9E-B42A5CBD630C

Q36877036-3CD28DFB-CE0E-4581-8D8A-5EF6CA42E96B

Q36877036-3F7BDBF1-86BB-462A-AB14-2AF492EA1069

Q36877036-4124E35F-D86A-4F53-ABD4-5C94704D19D1

Q36877036-464052FA-A5DE-4B03-B3C9-792B7E21620E

Q36877036-6A159426-87A5-4D20-95C3-FDE4C9D396AD

P304

Q36877036-CCAED75D-31BF-4532-AC0A-B0FC66072BD1

P31

Q36877036-2B7F47BF-4C4E-4F93-B7EE-3DDEE71BF22E

P356

Q36877036-69DC2978-BFBA-4857-B910-A4120DB776FC

P407

Q36877036-0D0D322E-205F-4D5D-9E33-520264E26791

P433

Q36877036-2CE33D92-4E43-43CF-A58C-5A0B7F110B04

P478

Q36877036-211B0A24-0985-4C3D-8C3F-4EC673F06E5D

P50

Q36877036-EF56A9BD-6D26-4B72-B960-6722CE17E24A

P577

Q36877036-26CEE80C-9986-41F7-BB9F-464E2A2DFCFE

P698

Q36877036-79679D1A-17D0-42EA-AEB8-54359D20F6E3

P932

Q36877036-513B194F-A028-4501-9796-6E2954D879C7

P356

JCO.2011.35.8135

P1433

Journal of Clinical Oncology

P1476

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

@en

P2093

Benjamin Esterni

http://www.w3.org/2001/XMLSchema#string

Bruno Quesnel

http://www.w3.org/2001/XMLSchema#string

C L Beach

http://www.w3.org/2001/XMLSchema#string

Christian Recher

http://www.w3.org/2001/XMLSchema#string

Claude Gardin

http://www.w3.org/2001/XMLSchema#string

François Dreyfus

http://www.w3.org/2001/XMLSchema#string

Lionel Adès

http://www.w3.org/2001/XMLSchema#string

Norbert Vey

http://www.w3.org/2001/XMLSchema#string

Odile Beyne Rauzy

http://www.w3.org/2001/XMLSchema#string

Raphael Itzykson

http://www.w3.org/2001/XMLSchema#string

P2860

Translating the Histone Code

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Epigenetic reprogramming in mammalian development

International scoring system for evaluating prognosis in myelodysplastic syndromes

Epigenetics in cancer

Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.

Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.

P304

3322-3327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.35.8135

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21788559

http://www.w3.org/2001/XMLSchema#string

P932

4859209

http://www.w3.org/2001/XMLSchema#string